CanDiag is pursuing development and commercialization of a blood test to accurately detect cancer and reduce unnecessary breast biopsies.
CanDiag, Inc., a UNC Charlotte spin-out, has developed a patented antibody based blood test to diagnose breast cancer. In a study involving women with suspicious mammograms, CanDiag's test identified invasive breast cancer with 100% sensitivity. Our mission is to initially offer diagnostics for breast cancer. Our vision is to offer products ranging from accurate cancer screening and imaging tests to targeted drug delivery therapies.